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Poster Session I 67181Univariate analysis of pre and post transplant variables
Variable PFS P value OS P value
Prior Radiation Therapy 0.05 (11.9 v 24.2
months)
0.0003 (25.3 v 68.6
months)
Prior Radiation Therapy
(excluding pateints who
received TBI)
0.03 (10 v 23.7
months)
0.02 (24.5 v 57.3
months)
Prior Radiation Therapy 0.35 (11.9 v 28.4 0.045 (32.7 v 57.3IDENTIFICATION OF GRAFT-VERSUS-MYELOMA TARGET ANTIGENS
FOLLOWING SYNGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Biernacki, M.A.1,2, Marina, O.1,2, Liu, F.3, Soiffer, R.J.2, Ritz, J.1,2,
Anderson, K.C.2, Wu, C.J.1,2. 1 Dana-Farber Cancer Institute, Boston,
MA; 2 Dana-Farber Cancer Institute/Brigham & Women’s Hospital/-
Harvard Medical School, Boston, MA; 3 Dana-Farber Cancer Institute,
Boston, MA.
Allogeneic hematopoietic stem cell transplantation (HSCT) re-
mains the sole curative therapy for multiple myeloma, but the tar-
gets of the graft-versus-myeloma (GvM) response following
HSCT are not well defined. Graft-versus-host (GvH) responses
against minor histocompatibility antigens in allogeneic transplanta-
tion can complicate the elucidation of tumor-specific targets. In-
stances in which syngeneic HSCTs result in durable remissions
provide opportunities to identify tumor-specific antigens. Since do-
nor and host are genotypically identical, immune responses follow-
ing syngeneic HSCT presumably target antigens unique to the
tumor, rather than alloimmune antigens. We therefore performed
a detailed analysis of the humoral immune response in a 47 year
old patient with myeloma who underwent myeloablative syngeneic
HSCT that resulted in a durable clinical remission lasting more
than 1.5 years. To identify antigens associated with GvM in an un-
biasedmanner, we applied this patient’s 3, 6, 12, and 16month post-
HSCT plasma against high density protein microarrays consisting
of8000 open reading frames (Invitrogen ProtoArray, v4.0). Bioin-
formatic analysis yielded 16 candidate antigens representing 14
unique genes that elicited increased post-HSCT antibody reactivity
compared to pre-HSCT plasma, donor plasma, and age-, sex-, and
parity-matched normal controls. Most candidate antigens represent
intracellular proteins with known functions, including signal trans-
duction, transcriptional regulation, apoptosis, and immunoregu-
lation; however, two have unknown functions. The subset of
candidate antigens that have been validated by immunoprecipita-
tion of individual recombinant proteins with patient plasma in-
cludes PIM1 and RELA, both known oncogenes, and PDGFRB,
a cell surface receptor tyrosine kinase. Antibodies reactive against
PDGFRB, PIM1, and RELA temporally concur with the patient’s
early achievement of clinical remission, supporting a close associa-
tion between humoral immunity and GvM effects. Our findings
agree with previous observations that clinically evident anti-mye-
loma immunity is associated with polyclonal humoral immunity.
Ongoing studies will further characterize the generalizability of im-
mune responses against these candidates among myeloma patients,
define whether these targets elicit coordinated T cell responses, and
elucidate their potential as novel immunogens for targeted immu-
notherapy against multiple myeloma.(patients with available
cytogenetics only) 69/101
months) months)
TBI containing Regimen
(Yes v No)
0.72 0.42
Age (less than 55 or more
than 55)
0.03 (23.3 v 12.7
months)
0.24
Gender 0.14 0.41
Ig subtype 0.14 0.89
Stage 0.36 0.66
Status at Transplant
(CR1PR v Others)
0.0001 (22.4 v 9.8
months)
0.07 (52.1 v 42
months)
Status post Transplant
(CR v Others)
0.93 (15.2 v 18.4
months)
0.84 (51.2 v 47.1
months)
CD34 millon cells/Kg infused
(less than 5.5 vmore than 5.5)
0.04 (12.4 v 23.3
months)
0.18
Time to transplant (less than 9
months v more than 9
months)
0.70 0.31
Cytogenetics (Ch 13 del v
normal v others)
0.31 0.15
Number of prior regimens
(1–2 v[more than 2)
0.14 0.11
B2M (less than 3 v more than 3) 0.31 0.68
LDH (less than 300 v more than
300)
0.41 0.38
Maintenance therapy (Yes v No) 0.99 0.47182
CONVENTIONAL CHEMOTHERAPY WITH INTERFERON VERSUS CON-
VENTIONAL CHEMOTHERAPY FOLLOWED BY HIGH DOSE CHEMOTHER-
APY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED
PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA. A META-ANALY-
SIS OF RANDOMIZED CLINICAL TRIALS
Ayala, E., Kumar, A. University of South Florida/H. Lee Moffitt Cancer
Center, Tampa, FL.
Purpose: High dose chemotherapy (HDT) followed by autolo-
gous stem cell transplantation has been used as part of the initial
therapy of patients with untreated advanced follicular lymphoma
and has been compared with standard dose therapy (SDT)with vari-
able benefit in randomized clinical trials (RCT). Therefore, to ad-
dress the variability in results, we undertook a systematic review
of all RCT that evaluated the outcome of upfront use of HDT ver-
sus SDT. Patients and Methods: We performed a wide search in
the main computerized databases of interest (MEDLINE, EM-
BASE, LILACS, CANCERLIT, and Cochrane Library). Two re-
viewers independently extracted study data, interventions and
outcomes. Data were pooled on benefits and harms as per the
methods recommended by the Cochrane Collaboration. Results:
In total the search of electronic databases yielded 67 trials ofHDT in follicular lymphoma, out of which 3 were RCTs accruing
878 patients. Mature data for OS was available only for one trial
showing no statistical difference between HDT and SDT (hazard
ratio 1.32; 95% CI, 0.60 to 2.89; p 5 0.489). However, HDT was
associated with a significant improvement in EFS (hazard ratio
0.65; 95% CI, 0.46 to 0.92; p5 0.014). Additionally, treatment re-
lated mortality was not different between both therapies (odds ratio
0.82; 95% CI, 0.03 to 22.55, p 5 0.9). The incidence of secondary
hematologic malignancies was also not statistically different (odds
ratio 3.25; 95% CI, 0.31 to 34.54; p 5 0.328). Conclusions:
HDT is associated with a significant improvement in EFS in ad-
vanced follicular lymphoma when used as part of the primary ther-
apy without any significant adverse effect in terms of treatment
related mortality and incidence of secondary hematologic malig-
nancies. Impact on overall survival cannot be determined until ma-
ture data is available.183
HISTORY OF PRIOR RADIATION THERAPY PREDICTS POOR PROGRES-
SION FREE SURVIVAL AND OVERALL SURVIVAL IN AFRICAN AMERICANS
WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANS-
PLANTATION
Khaled, Y.A.1, Abidi, M.H.2, Janakiraman, N.3, Kato, K.1,
Hanbali, A.3, Levine, J.E.1, Ferrara, J.L.1, Mineishi, S.1. 1 University
of Michigan, Ann Arbor, MI; 2 Karmanos Cancer Institute, Detroit,
MI; 3 Henry Ford Hospital, Detroit, MI.
African Americans (AA) are twice as likely to suffer frommultiple
myeloma (MM) and the mortality is twice as high as that of Cauca-
sian Americans. However, limited literature is available regarding
the outcomes after autologous stem cell transplantation (ASCT)
in this population. We report here the outcomes of the largest co-
hort to date in AA with MM after ASCT. We evaluated the out-
comes of 101 consecutive AA patients who underwent ASCT for
MM between 2/1996 and 6/2006 at 3 centers. All patients received
